Please login to the form below

Not currently logged in

Kite partners with Shoreline Biosciences to develop allogeneic cell therapies

The deal could be worth a total of up to $2.3bn, with Shoreline receiving an undisclosed upfront payment

Kite – a Gilead company – has entered into a strategic partnership with Shoreline Biosciences to develop novel allogeneic cell therapies across a range of cancer targets.

Shoreline will bring its expertise in induced pluripotent stem cells (iPSC) and genetic reprogramming to the partnership, while Kite will bring its expertise in cell therapy development, commercialisation and manufacturing.

Together, the companies will work to develop novel allogeneic candidates for use in haematologic malignancies.

“The combined strength of Kite’s leadership in CAR T-cell therapies and our cutting-edge iPSC platform will potentially accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities and deliver transformational treatment options for cancer,” said Kleanthis G. Xanthopoulos, co-founder, chairman and chief executive officer of Shoreline.

Initially, the collaboration will focus on chimeric antigen receptor (CAR) natural killer (NK) targets. Kite will also retain an option to expand the collaboration to include an iPSC CAR macrophage programme for an undisclosed target, to be agreed on after completion of the deal.

Shoreline will receive an undisclosed upfront payment and will also be eligible to receive additional payments that could make the deal worth over $2.3bn. In addition, Shoreline will receive royalties based on the achievement of certain development and commercial milestones.

“As the leader in cell therapy, we are focused on investing in and delivering the most promising opportunities to further optimise the therapeutic potential of cell therapy,” said Mert Aktar, vice president of corporate development and strategy at Kite.

“We are excited about the potential of Shoreline’s next-generation approach to allogeneic development, and how our collaboration can accelerate this research across different leukaemias and lymphomas,” he added.

Earlier this year, Kite signed a research collaboration agreement with Oxford BioTherapeutics (OBT) to develop novel targets in a range of oncology indications.

The collaboration will evaluate five novel targets for a number of haematologic and solid tumour indications, according to a press release.

The novel drug targets, already identified using OBT’s OGAP discovery platform, will be validated by the Oxford, UK-based oncology specialist as part of the Kite collaboration.

As part of the agreement, Kite and Gilead will obtain an exclusive right to develop and commercialise any therapies resulting from the collaboration based on the specified targets or antibodies.

Article by
Lucy Parsons

17th June 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....